Inhibrx Biosciences, Inc. INBX
Super Investor & Insider
1
Fondi che lo detengono
#813
Rank consenso
1.4%
% dei portafogli
$96.7M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Viking Global Investors · Viking Global Investors | 0.27% | — | 1,437,705 | $96.7M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases. The company’s primary objective is to innovate targeted therapies that can address significant unmet medical needs in the areas of oncology, rare diseases, and autoimmune cond…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees109
TickerINBX
Statistics
Market Cap$1.37B
Revenue (TTM)$1.3M
Net Income-$140.1M
Net Margin-10773.5%
EPS$-9.04
P/E0.20
P/S1009.72
P/B-69.32
EV/EBITDA-11.03
ROE-354.7%
Dividend Yield—
Price$93.71
Data: Twelve Data · Revenue = mcap / P/S